Abstract 432P
Background
Although extravasation (EV) is an established complication of parenteral chemotherapy, it often goes under-documented and underestimated. The incidence and severity of extravasation can be influenced by patient, drug or procedure related factors. An understanding of the risk factors and predictors promotes precaution during chemotherapy.
Methods
A prospective study was conducted for one year in patients satisfying study criteria. Patient information such as demographics, history, disease, treatment regimen and EV related information was documented. Severity of EV was established using CTCAE 4.3. The captured data was subjected to appropriate statistical analysis using SPSS ver. 20.
Results
Amongst the 217 patients reviewed 46(21.20%) experienced EV [Grade 2(67.39%) and Grade 3(32.61%)]. Cluster statistics revealed age, gender and ambulation to be the most important predictors. Ambulation caused an 8 fold increase in the risk of EV (p < 0.001, [2.01-14.2]). Females were observed to be 2.5 times susceptible to EV (p = 0.001, [2.5-5.9]) than males. Progressive age i.e. beyond 60 years the risk of EV increases 2.02 times (p = 0.005, [1.3-3.8]). Additionally, age (p = 0.007, OR: 2.24 [1.22-6.71]), sex (p = 0.010, OR: 2.71 [1.38-7.64]), ambulation (p = 0.001, OR: 4.67 [2.09-4.90], co-morbidities (p = 0.029, OR: 3 [2.17-5.67] and the use of irritants (p = 0.007, OR: 2.25 [1.27-3.76] increased the risk of the patient getting severe EV injury.
Conclusions
Patient, drug and procedure related risk factors influence the incidence of chemotherapy induced EV injury. In the studied population, age, gender, ambulation and co-morbidities were established as predictors of extravasation. Multi-disciplinary approach and patient counselling can contribute to minimizing the discomfort and complication of EV.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
All Authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract
371P - Clinical utility of Encyclopedic tumour analysis to treat patients advanced refractory head and neck cancers
Presenter: Rajnish Nagarkar
Session: Poster display session
Resources:
Abstract
372P - Real-world fusion landscape in advanced Chinese pancreatic cancer using next generation sequecing: A multicenter study
Presenter: Yiyu Shen
Session: Poster display session
Resources:
Abstract
373P - Molecular profiling of non-small cell lung cancer (NSCLC) in Asia with targeted next-generation sequencing (NGS): Interim analysis of a co-operative group study (ATORG-001)
Presenter: Aaron Tan
Session: Poster display session
Resources:
Abstract
374P - Circulating tumour DNA (ctDNA) identifies actionable genetic alterations in Middle Eastern and Asian (MEA) patients diagnosed with carcinoma of unknown primary (CUP)
Presenter: Nir Peled
Session: Poster display session
Resources:
Abstract
375P - Whole-exome sequencing of tumour-only samples reveals the association between somatic alterations and clinical features in pancreatic cancer
Presenter: Huixin Lin
Session: Poster display session
Resources:
Abstract
376P - Adoption of molecular testing in breast cancer in a tertiary care center in a developing country
Presenter: Prasanta Dash
Session: Poster display session
Resources:
Abstract
377P - NGS in advanced NSCLC in a developing country: Ready for prime time?
Presenter: Amrith B P
Session: Poster display session
Resources:
Abstract
378P - Germline BRCA1/2 testing: Trend in Tan Tock Seng Hospital Singapore
Presenter: Chia Wei Lim
Session: Poster display session
Resources:
Abstract
379P - Study of germline mutations in high risk cancer patients from a tertiary care center in India
Presenter: Padmaj Kulkarni
Session: Poster display session
Resources:
Abstract